Slayback Pharma

21 articles about Slayback Pharma

• Azurity Pharmaceuticals Acquires Slayback Pharma

  9/27/2023

  Azurity Pharmaceuticals, Inc. ("Azurity") is pleased to announce the closing of its acquisition of Slayback Pharma LLC ("Slayback") today from existing investors including KKR

• Endo Announces Agreement with Slayback Pharma to Distribute Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection)

  4/26/2023

  Endo International plc (OTC: ENDPQ) announced today that its subsidiaries Endo Ventures Limited and Par Pharmaceutical, Inc. (collectively "Endo") have executed an agreement with Slayback Pharma LLC to distribute Slayback's Prevduo ™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe on an exclusive basis in the U.S.

• Slayback Appoints Pete Meyers as Chief Financial Officer

  6/25/2021

   Slayback Pharma LLC announced today the appointment of Pete A. Meyers as its Chief Financial Officer.

• Slayback Appoints Paul Campanelli to Board of Directors

  2/26/2021

  Slayback Pharma LLC, a Princeton, NJ based specialty pharmaceutical company, announced the appointment of Paul Campanelli to its Board of Directors.

• Slayback Appoints Dave Picard as Chief Commercial Officer

  2/16/2021

  Slayback Pharma LLC announced the appointment of Dave Picard as the Company's Chief Commercial Officer.

• Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, generic equivalent of Taytulla®

  2/4/2021

   Slayback Pharma LLC announces that it has launched Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg and fulfilled customer orders for the product.  With the launch, Slayback has effectively secured 180-day period of CGT exclusivity. 

• Slayback Pharma announces FDA approval of Merzee, generic equivalent of Taytulla® with a Competitive Generic Therapy (CGT) Designation

  12/18/2020

   Slayback Pharma LLC announced today that it has received final approval for its Abbreviated New Drug Application (ANDA) for Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg from the USFDA with a Competitive Generic Therapy Designation.  Merzee is an AB-rated generic equivalen

• Slayback Pharma announces approval and launch of Icatibant Injection 30 mg/3 ml (10 mg/ ml), generic equivalent of Firazyr®.

  9/2/2020

  Slayback Pharma, LLC announced today that it has received final approval for Icatibant Injection 30 mg/3 ml (10 mg/ml) in a Prefilled Syringe - a generic equivalent of Firazyr.

• Slayback Pharma Appoints Lori A. Hoffman as Head of Alliance Management

  8/17/2020

  Slayback Pharma LLC ("Slayback"), a privately-held, specialty pharmaceutical company, announced today the appointment of Lori A. Hoffman as Head of Alliance Management.  Lori is an experienced, pharmaceutical executive with a 30-year track record in the industry, where she has held various roles of increasing responsibility.  Lor

• Slayback Pharma announces investment of $50 million by The Everstone Group

  1/6/2020

  Slayback Pharma LLC announced an agreement with The Everstone Group to invest up to US$50 million in Series B funding.

• Slayback Pharma announces approval and immediate launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in 200 mcg/ 50 mL and 400 mcg/ 100 mL (4 mcg/mL) vials, generic equivalent of Precedex™ 4 mcg/ mL

  12/10/2019

  Slayback Pharma LLC announced the final approval and launch in the United States of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection.

• Slayback Pharma announces approval of Hydroxyprogesterone Caproate Injection, USP 250 mg/ 1 mL in a single-dose vial, generic equivalent of Makena® Injection 250 mg/ 1 mL

  3/25/2019

  This is the second ANDA approved by the FDA for Hydroxyprogesterone Caproate Injection in a preservative-free single-dose vial that is therapeutically equivalent to Makena.  

• Slayback Pharma announces launch of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena® Injection 1,250 mg/ 5 mL multi-dose vial

  1/21/2019

  Slayback Pharma LLC announced today that it has launched its first commercial product Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 ml.

• Slayback Pharma announces FDA approval of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena® Injection 1,250 mg/ 5 mL multi-dose vial

  1/2/2019

  Slayback Pharma LLC announced today that the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application ("ANDA") for Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 ml.

• Slayback Pharma Appoints Dr Girish Jain as Head of Global R&D

  7/24/2018

  Slayback Pharma ​ LLC ("Slayback"), a privately held pharmaceutical research and development company, announced today the appointment of Dr Girish Jain as Senior Vice President and Head of Global R&D. Dr Jain will be based out of Slayback's Hyderabad, India office.

• Slayback Pharma Appoints Joan Janulis as Head of Global Regulatory Affairs

  7/16/2018

  Slayback Pharma LLC announced the appointment of Joan Janulis as the Senior Vice President of Global Regulatory Affairs.

• Ajay Singh of Slayback Pharma wins Ernst and Young's Entrepreneur Of The Year® 2018 Award in Life Sciences Category in New Jersey

  6/29/2018

  Slayback Pharma today announced that Founder & CEO, Ajay Singh, of Slayback Pharma LLC is the winner of the 32nd Ernst and Young's Entrepreneur Of The Year® 2018 Award in the Life Sciences category in New Jersey.

• 

  Biotech Leaders Top List of Ernst & Young 2018 Entrepreneur of the Year Candidates

  4/27/2018

  Every year for the last 32 years, Enrst & Young has awarded entrepreneurs in various categories, including Life Science, Consumer Products and Retail, Distribution and Manufacturing and other categories. The awards are given in June. The finalists have been announced. Here’s a look at some of the...

• Slayback Pharma Appoints Abhijit Mukherjee as Senior Advisor

  4/2/2018

  Abhijit will advise the company on strategic and operational matters.

• Slayback Pharma Appoints Patrick Mcintosh As Head Of Commercial Operations

  6/28/2017